Navigation Links
Agendia Raises US $23 Million in Series E Financing
Date:9/22/2009

e doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
2. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
3. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
4. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
5. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
6. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
7. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
8. Agendia Appoints VP of Business Development
9. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
10. Agendia Appoints New Chief Financial Officer
11. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... OAKS, Calif. , July 25, 2014 ... Board of Directors today declared a $0.61 per share ... will be paid on Sept. 5, 2014, to all ... on Aug. 14, 2014.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
(Date:7/25/2014)... July 25, 2014 The Conferee Networking ... Topics for Conferee Networking. These two-hour sessions provide a ... meet and resolve problems, discuss new techniques, or brainstorm ... to submit a topic for consideration is August 31, ... . The Conferee Networking committee will review the topics, ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... FRAZER, Pa. and MAISONS-ALFORT, France, Jan. 24 /PRNewswire-FirstCall/,-- ... that the European,Committee for Medicinal Products for Human ... a positive opinion regarding EFFENTORA(TM), the,company,s fentanyl buccal ... EFFENTORA European new drug application for the treatment ...
... DIEGO, Jan. 24 Biomatrica, the biostability company,that ... temperature, has introduced RNAstable(TM) for preserving RNA at ... shipping., Interest in RNA has skyrocketed over ... gene silencer and in gene expression studies. However, ...
Cached Biology Technology:Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 3
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... Institute for Medical Research have identified the functions ... crucial to triggering the mating process in mice. , ... mouse detect pheromones that indicate when a female is ... if the female mouse is ovulating and ready to ... mating. Stowers, researchers believe mice developed this system through ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2It takes two to court 2It takes two to court 3
... is uniquely a "dual" sense, in that the brain perceives ... nose rather than the mouth. In the August 18, 2005, ... of chocolate activated different brain regions according to whether the ... or through the nose. , In a joint research effort ...
... cancer melanoma, studying functional tissue rather than cell ... development, according to new research from a Howard ... School of Medicine. , Though multiple genetic alterations ... been able to establish a direct causal link ...
... a small molecule of RNA called microRNA ?a chemical cousin ... protein involved in the early development of heart muscle. , ... Nature, may aid scientists in their understanding of how a ... cell, as well as offer researchers a way to predict ...
Cached Biology News:Nose odors and mouth odors: The brain distinguishes 2Nose odors and mouth odors: The brain distinguishes 3Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack 2Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack 3MicroRNA tweaks protein that controls early heart development 2MicroRNA tweaks protein that controls early heart development 3
...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Integrins Sampler Kit 10g each...
Biology Products: